PL3982956T3 - Potrójna kompozycja farmaceutyczna na zakażenie białkowe - Google Patents

Potrójna kompozycja farmaceutyczna na zakażenie białkowe

Info

Publication number
PL3982956T3
PL3982956T3 PL20823121.7T PL20823121T PL3982956T3 PL 3982956 T3 PL3982956 T3 PL 3982956T3 PL 20823121 T PL20823121 T PL 20823121T PL 3982956 T3 PL3982956 T3 PL 3982956T3
Authority
PL
Poland
Prior art keywords
proteinaceous
infection
pharmaceutical composition
triple
triple pharmaceutical
Prior art date
Application number
PL20823121.7T
Other languages
English (en)
Inventor
Joshua O. Atiba
Original Assignee
Joshua O. Atiba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/504,723 external-priority patent/US20200000829A1/en
Application filed by Joshua O. Atiba filed Critical Joshua O. Atiba
Publication of PL3982956T3 publication Critical patent/PL3982956T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL20823121.7T 2019-06-14 2020-06-15 Potrójna kompozycja farmaceutyczna na zakażenie białkowe PL3982956T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962861855P 2019-06-14 2019-06-14
US16/504,723 US20200000829A1 (en) 2018-06-27 2019-07-08 Therapy and prevention of prion protein complex infections
US16/565,242 US10729705B2 (en) 2018-06-27 2019-09-09 Therapy and prevention of prion protein complex infections in non-human animals
PCT/US2020/037787 WO2020252475A1 (en) 2019-06-14 2020-06-15 Triple pharmaceutical composition for proteinaceous infection

Publications (1)

Publication Number Publication Date
PL3982956T3 true PL3982956T3 (pl) 2024-10-28

Family

ID=73782140

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20823121.7T PL3982956T3 (pl) 2019-06-14 2020-06-15 Potrójna kompozycja farmaceutyczna na zakażenie białkowe

Country Status (21)

Country Link
EP (1) EP3982956B1 (pl)
JP (1) JP7645201B2 (pl)
KR (2) KR20250161037A (pl)
CN (2) CN120771163A (pl)
BR (1) BR112021025253A2 (pl)
CA (1) CA3142164A1 (pl)
DK (1) DK3982956T3 (pl)
ES (1) ES2984684T3 (pl)
FI (1) FI3982956T3 (pl)
HR (1) HRP20241019T1 (pl)
HU (1) HUE068048T2 (pl)
LT (1) LT3982956T (pl)
MX (1) MX2021015266A (pl)
MY (1) MY210598A (pl)
PL (1) PL3982956T3 (pl)
PT (1) PT3982956T (pl)
RS (1) RS65836B1 (pl)
SG (1) SG11202113265PA (pl)
SI (1) SI3982956T1 (pl)
SM (1) SMT202400304T1 (pl)
WO (1) WO2020252475A1 (pl)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189703B2 (en) 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
AU2003256496A1 (en) * 2002-07-12 2004-02-02 The Research Foundation Of State University Of New York Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations
KR100538780B1 (ko) * 2002-09-10 2005-12-23 주식회사 브레인트로피아 미노사이클린을 유효성분으로 함유하는 치매 및 기억력감퇴의 예방 및 치료용 조성물
CA2499599A1 (en) * 2002-09-17 2004-04-01 New York University Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
CN1960781A (zh) * 2004-04-14 2007-05-09 沃尼尔·朗伯有限责任公司 治疗阿尔茨海默氏病的治疗组合
WO2013061161A2 (en) * 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
US20140271923A1 (en) * 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
ES2626398T3 (es) 2014-08-18 2017-07-24 Fabrizio De Silvestri Empleo en una única píldora / comprimido / capsula de minociclina, acicloguanosina, atorvastatina y vitamina D3 en el tratamiento de la artritis reumatoide
DE102016208567A1 (de) * 2016-05-19 2017-11-23 Heraeus Medical Gmbh Polymerlösung zur Viscosupplementation
US20190358184A1 (en) * 2016-12-13 2019-11-28 Ecole Polytechnique Federale De Lausanne Methods of treating amyloid-beta peptide diseases
US10350226B1 (en) * 2018-06-27 2019-07-16 Joshua O. Atiba Therapy and prevention of prion protein complex infections

Also Published As

Publication number Publication date
KR20220020832A (ko) 2022-02-21
FI3982956T3 (fi) 2024-08-06
KR102878748B1 (ko) 2025-10-29
CA3142164A1 (en) 2020-12-17
CN114007609A (zh) 2022-02-01
MY210598A (en) 2025-10-01
KR20250161037A (ko) 2025-11-14
BR112021025253A2 (pt) 2022-04-12
MX2021015266A (es) 2022-01-18
PT3982956T (pt) 2024-07-26
EP3982956A4 (en) 2023-05-03
SI3982956T1 (sl) 2024-09-30
HRP20241019T1 (hr) 2024-11-08
EP3982956B1 (en) 2024-06-12
SMT202400304T1 (it) 2024-11-15
JP2022537132A (ja) 2022-08-24
LT3982956T (lt) 2024-08-26
RS65836B1 (sr) 2024-09-30
EP3982956A1 (en) 2022-04-20
ES2984684T3 (es) 2024-10-30
JP7645201B2 (ja) 2025-03-13
CN120771163A (zh) 2025-10-14
HUE068048T2 (hu) 2024-12-28
DK3982956T3 (da) 2024-07-22
WO2020252475A1 (en) 2020-12-17
SG11202113265PA (en) 2021-12-30

Similar Documents

Publication Publication Date Title
GB202019241D0 (en) Pharmaceutical composition
GB201911517D0 (en) Pharmaceutical composition
IL290469A (en) Oral pharmaceutical preparation
SI3908321T1 (sl) Farmacevtski sestavek
IL285728A (en) Pharmaceutical composition
AU2020356348B2 (en) Pharmaceutical compounds
PL3949952T3 (pl) Kompozycja farmaceutyczna
SG11202113265PA (en) Triple pharmaceutical composition for proteinaceous infection
EP4034567A4 (en) PHARMACEUTICAL COMPOSITIONS WITH POH DERIVATIVES
GB202018068D0 (en) Pharmaceutical composition
GB202010340D0 (en) Pharmaceutical composition
EP3903782A4 (en) PHARMACEUTICAL COMPOSITION
EP3806838A4 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES
HK40079778A (en) Pharmaceutical compositions
EP4066852A4 (en) PHARMACEUTICAL COMPOSITION
HK40078444A (en) Pharmaceutical composition comprising selexipag
HK40067652A (en) Pharmaceutical composition comprising ensifentrine
HK40059385A (en) Pharmaceutical composition
HK40065721A (en) Pharmaceutical formulations
HK40077614A (en) Pharmaceutical compounds
HK40068353A (en) Cannabidiol pharmaceutical compositions
HK40076183A (en) Pharmaceutical compounds
GB202020504D0 (en) Pharmaceutical composition
HK40068990A (en) Pharmaceutical compounds
GB202019237D0 (en) Pharmaceutical composition